Policy

Weekly Psychedelic Policy Briefing, Nov 13, 2026

By Joe Moore
featured image
Share
LINKEDIN FACEBOOK TWITTER
Vital 6 is coming soon! 300 250

HHS announced up to $4.9 million for ibogaine research and a $20 million funding opportunity for rapid-acting psychiatric drugs. Also this week: Compass Pathways’ completed psilocybin application, Senate report language on VA planning, higher proposed DEA quotas and a California research solicitation for veterans.

HHS Announces Ibogaine Research Commitment and $20 Million Rapid-Acting Drug Research Opportunity

HHS said Nov. 12 that the Advanced Research Projects Agency for Health (ARPA-H) will commit up to $4.9 million over five years to develop ibogaine as a potential treatment for post-traumatic stress disorder (PTSD) and other serious mental illnesses. ARPA-H selected two teams. Mark Cuban Cost Plus Drug Company will lead work on the regulatory, clinical and manufacturing basis for a domestically made ibogaine hydrochloride product. Beond, Inc., will provide clinical data on safety, dosing, efficacy and durability; the company said it will give ARPA-H de-identified data from 250 patients treated at its clinic in Cancún, Mexico.

HHS said the support is for preparatory work only, with funding contingent on each team meeting research milestones. The money supports investigational new drug applications, a supply of clinical-grade ibogaine and domestic manufacturing, and does not pay for patient treatment or human-subject research, authorize clinical trials or establish FDA approval. HHS also said ibogaine carries serious risks, including potentially life-threatening heart rhythm problems.

In the same announcement, HHS said the National Institute of Mental Health (NIMH) published a $20 million funding opportunity for a research network on rapid-acting psychotropic drugs. The notice, RFA-MH-27-150, names ketamine, esketamine, psilocybin and MDMA, identifying the latter two as late-stage investigational drugs. It requires studies of investigational drugs to run under an FDA investigational new drug application. The notice also lists up to $2 million from the National Institute on Drug Abuse in fiscal 2027.

HHS described the ibogaine commitment and the NIMH funding opportunity as advancing President Trump’s April directive on psychedelic research. Psychedelics Today (PT) reported Oct. 27 that the FDA was taking public comment on how early ibogaine trials should be designed. Reuters reported that HHS Secretary Robert F. Kennedy Jr. said a second ARPA-H ibogaine effort, aimed at substance use disorder, would be announced by the end of 2026. The NIMH application window opens Dec. 5, with the first applications due Jan. 5, 2027. HHS said NIMH award recipients will be announced in summer 2027.

Compass Completes COMP360 Application; Reuters Reports FDA Voucher Pilot Shelved, HHS Says It Is Ongoing

Compass Pathways said Nov. 9 that it had finished submitting its new drug application to the FDA for COMP360, an investigational synthetic psilocybin product for treatment-resistant depression. The company said the application rests on two Phase 3 trials and a Phase 2b study that each met its primary endpoint, with more than 1,000 participants in total.

PT reported in the Oct. 27 briefing that Compass then expected to finish its rolling submission in the fourth quarter. In its third-quarter release, Compass said its Commissioner’s National Priority Voucher could shorten FDA review to one to two months, while cautioning that the voucher pilot “may not actually lead to a faster FDA review or approval process.” On Nov. 12, Reuters reported, citing six sources and internal documents, that the FDA has shelved the voucher pilot and that career scientists have resumed overseeing review timelines for the nine drugs still in it. HHS spokesperson Emily Hilliard said the pilot is ongoing, and an FDA spokesperson told BioSpace that agency career staff continue to evaluate applications already granted a voucher. BioSpace reported that Compass and Usona Institute both hold vouchers.

Submission is not approval. As of Nov. 13, Compass had not announced that the FDA accepted the application for review or set a decision date. In its Nov. 9 release, Compass said it targets a U.S. launch in the first half of 2027, subject to FDA approval, and that the product must be rescheduled by the DEA before it can be sold.

Senate Appropriators Call for VA Planning on Psychedelic Therapies

The Senate Appropriations Committee released its fiscal 2027 Military Construction-VA and Agriculture-FDA bills Nov. 10. In the explanatory statement accompanying the VA bill, the committee wrote that it “directs the Secretary of Veterans Affairs to develop a plan to expand VA-led clinical and implementation-focused research,” so the department is “prepared to responsibly integrate any FDA-approved therapies into clinical care.”

The committee has not voted on either bill, and the statement is not law. It calls for the VA secretary to brief the House and Senate appropriations committees on the plan not later than 180 days after the bill’s enactment. It also encourages the VA to consider prioritizing research on treatment-resistant PTSD, “including but not limited to ibogaine and other psychedelic compounds,” and to develop a way to collect voluntary, de-identified data on veterans who travel abroad for treatments such as ibogaine.

The Agriculture-FDA statement names MDMA, psilocybin, ibogaine and 5-MeO-DMT and encourages the FDA to work with the VA, the Department of Defense and the National Institutes of Health on clinical trials and public-private research collaborations, “with the FDA maintaining its independent regulatory authority as an observer.” It requests an update within 180 days of enactment.

Separately, the House version of the fiscal 2027 defense bill includes amendments that would extend the military psychedelic research program to 2033, as PT reported Aug. 3. A committee markup date for the Senate bills has not been announced.

DEA Proposes Higher 2027 Production Quotas for Four Psychedelics

The DEA published proposed 2027 aggregate production quotas in the Federal Register on Nov. 10. The proposed quotas, compared with the 2026 figures reported by Marijuana Moment, are: MDMA, 33,296 grams versus 12,000; ibogaine, 12,002 grams versus 210; psilocybin, 60,000 grams versus 50,000; and psilocyn, 93,600 grams versus 80,000.

If finalized, the quotas would set nationwide production ceilings for registered manufacturers in 2027. The proposal does not change any substance’s schedule or approve any product for treatment. The DEA wrote that the MDMA and ibogaine increases are meant “to support manufacturing activities related to the increased level of research and clinical trials,” and that the proposal aligns with Executive Order 14379 on addiction and Executive Order 14401, “Accelerating Medical Treatments for Serious Mental Illness.”

The notice treats marijuana as Schedule I for quota purposes and says separate quotas will cover the products moved to Schedule III in April: FDA-approved marijuana products and products made under a state medical marijuana license. Comments on the proposal, docket DEA-1730P, are due Dec. 10.

California Announces Up to $4 Million for Psychedelic Research With Veterans

The California Health and Human Services Agency issued a research-grant solicitation Nov. 10 offering up to $4 million for psychedelic treatment research through partnerships between California nonprofit academic research institutions and veteran communities. The state’s precision medicine program will administer grants lasting three to four years.

The solicitation is for research grants and does not create treatment access. The funding comes from AB 113, a budget trailer bill signed in 2026, according to the state. Letters of intent are due Dec. 18, and initial applications are due Feb. 19, 2027.

Also This Week

Marijuana rescheduling. In a Nov. 5 reply brief, the DEA renewed its request that the administrative law judge give no weight to a Government Accountability Office report on scheduling procedures, which its Oct. 29 brief called “not probative to the instant rescheduling analysis.” The Marijuana Herald, which posted the filings, reported that no deadline has been set for the judge’s recommendation.

FDA leadership. BioSpace reported that a Senate health committee vote on Heidi Overton’s nomination as FDA commissioner is scheduled for Nov. 18.

House hearing. The House Veterans’ Affairs Subcommittee on Health has scheduled an oversight hearing titled “Psychedelic-Assisted Therapies for Veterans: The Path Forward” for Nov. 18 at 2:15 p.m. Eastern.

Catch-up, Oct. 28 to Nov. 4

Usona application. Psychedelic Alpha reported Nov. 2 that Usona Institute had completed a new drug application submission to the FDA for psilocybin in major depressive disorder and holds a National Priority Voucher. Usona declined to comment to the outlet.

Congress. Rep. Steve Cohen (D-Tenn.) said the bill he introduced Oct. 29 would transfer scheduling authority from the attorney general to the HHS secretary and prioritize about 30 substances, including psilocybin and ibogaine, for reevaluation.

Idaho. Unofficial results compiled by Ballotpedia showed 66.27% voting against House Joint Resolution 4 on Nov. 3, with certification set for Nov. 24, according to the Idaho Capital Sun. The measure would have reserved legalization authority over marijuana, narcotics and other psychoactive substances to the Legislature; its defeat did not legalize those substances.

New Mexico. According to the Santa Fe Reporter, the New Mexico Department of Health said Oct. 30 that it would remove a landlord-approval requirement for renters from proposed rules governing psilocybin treatment at home. The rules remain proposed; PT covered the original home-treatment proposal Oct. 5.

Comments are due Nov. 18 on Groff Health Inc.’s application to import ibogaine, MDMA, psilocybin and psilocyn, and Nov. 20 on the FDA’s request for information on ibogaine trial design.


Psychedelics Today editors selected and edited the items in this briefing, using AI tools to assist with research and drafting. An editor checked each item against its sources before publication. Read our editorial standards.

Vital 6 is coming soon! 300 250
Joe Moore - CEO - Psychedelics Today

About the Author

Joe Moore

Joe Moore is the co-founder and CEO of Psychedelics Today, a leading media and education platform exploring the science and culture of psychedelics. Since 2016, he’s hosted hundreds of interviews with researchers, clinicians, and visionaries shaping the psychedelic revival. Joe also co-created Vital, a year-long training for practitioners, and teaches at the intersection of breathwork, philosophy, and integration. He lives in Colorado, where he leads Transpersonal Breathwork workshops and continues building psychedelic education worldwide.